Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have received an average rating of “Moderate Buy” from the thirteen research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $60.40.

IMCR has been the topic of a number of recent research reports. UBS Group set a $55.00 target price on Immunocore and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Morgan Stanley raised their price objective on shares of Immunocore from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research note on Wednesday, February 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Thursday, January 22nd. Finally, Zacks Research raised shares of Immunocore from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 7th.

Immunocore Stock Up 3.7%

IMCR stock opened at $32.05 on Monday. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.00 and a quick ratio of 5.97. The firm’s fifty day simple moving average is $34.77 and its 200-day simple moving average is $34.39. Immunocore has a 12 month low of $23.15 and a 12 month high of $40.71. The company has a market capitalization of $1.62 billion, a P/E ratio of -56.23 and a beta of 0.78.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.30) by $0.32. The company had revenue of $103.69 million for the quarter, compared to analyst estimates of $137.29 million. Immunocore had a negative net margin of 7.70% and a negative return on equity of 7.67%. The firm’s revenue was up 29.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.17 earnings per share. As a group, equities research analysts forecast that Immunocore will post -0.94 earnings per share for the current year.

Institutional Trading of Immunocore

Several institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC increased its position in shares of Immunocore by 51.6% in the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after buying an additional 311 shares in the last quarter. DNB Asset Management AS grew its stake in Immunocore by 6.4% in the 3rd quarter. DNB Asset Management AS now owns 8,116 shares of the company’s stock valued at $295,000 after acquiring an additional 488 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Immunocore by 37.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after acquiring an additional 572 shares in the last quarter. R Squared Ltd raised its position in Immunocore by 7.4% during the fourth quarter. R Squared Ltd now owns 8,849 shares of the company’s stock worth $307,000 after acquiring an additional 606 shares during the period. Finally, Virtus Investment Advisers LLC lifted its holdings in Immunocore by 5.3% during the second quarter. Virtus Investment Advisers LLC now owns 12,472 shares of the company’s stock valued at $391,000 after purchasing an additional 625 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.